β-谷甾醇靶向CDC25B抑制肝癌细胞增殖

王凯; 李卫; 李志芳; 纪会琼; 郭志伟; 曹俊秋

doi:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20220509.001

您当前的位置：

首页 >

文章列表页 >

β-谷甾醇靶向CDC25B抑制肝癌细胞增殖

技术研究 | 更新时间：2024-02-19

- β-谷甾醇靶向CDC25B抑制肝癌细胞增殖
- Mechanisms of β-sitosterol on Inhibiting the Proliferation of Hepatocellular Carcinoma Cells by Targeting CDC25B
- 中山大学学报（医学科学版） 2022年43卷第4期页码：675-684
- 作者机构：
  
  1.达州中医药职业学院公共基础部，四川达州 635000
  2.达州市疾病预防控制中心附属医院，四川达州 635000
  3.南充市中心医院影像科，四川南充 637000
  4.四川大学华西医院肝胆外科，四川成都610000
- 作者简介：
  
  WANG Kai； E-mail：WK18113396386@163.com
- 基金信息：
  
  四川省医学（青年创新）科研课题(Q20043)
- DOI：10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20220509.001
  中图分类号： R735.7
- 纸质出版日期：2022-07-20，
  
  收稿日期：2021-10-09，
扫描看全文
王凯,李卫,李志芳等.β-谷甾醇靶向CDC25B抑制肝癌细胞增殖[J].中山大学学报（医学科学版）,2022,43(04):675-684.

WANG Kai,LI Wei,LI Zhi-fang,et al.Mechanisms of β-sitosterol on Inhibiting the Proliferation of Hepatocellular Carcinoma Cells by Targeting CDC25B[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(04):675-684.
王凯,李卫,李志芳等.β-谷甾醇靶向CDC25B抑制肝癌细胞增殖[J].中山大学学报（医学科学版）,2022,43(04):675-684. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20220509.001.

WANG Kai,LI Wei,LI Zhi-fang,et al.Mechanisms of β-sitosterol on Inhibiting the Proliferation of Hepatocellular Carcinoma Cells by Targeting CDC25B[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(04):675-684. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20220509.001.

摘要

目的

探讨β-谷甾醇对肝癌细胞增殖的影响及其可能作用机制。

方法

通过SwissTarget和TargetNet数据平台预测β-谷甾醇的靶点、GEO2R分析GSE101728肝癌数据集中表达上调基因并分析两者共同基因，通过下载TCGA_LIHC数据矩阵分析得到细胞分裂周期25B（CDC25B）与肝癌临床分期和患者生存预后存在关系。CCK-8、细胞集落形成实验、流式细胞法检测β-谷甾醇作用下肝癌细胞HepG2和Hep3B细胞活力、细胞增殖、细胞周期分布和细胞凋亡情况；构建HepG2皮下移植瘤裸鼠模型分为Control组和β-谷甾醇组，β-谷甾醇组腹腔注射β-谷甾醇（50 mg/kg·d），测量移植瘤体积和质量，免疫组化检测Ki67表达水平；Western blot检测β-谷甾醇不同作用浓度和不同作用时间HepG2和Hep3B细胞系中CDC25B蛋白水平，构建稳定过表达CDC25B的HepG2和Hep3B细胞系并给予β-谷甾醇处理，同上方法检测HepG2和Hep3B细胞系细胞活力、细胞增殖、细胞周期分布和细胞凋亡情况。

结果

CDC25B表达水平，肝癌组织高于其癌旁组织（

0.05），TNM分期（T2-4）高于TNM分期（T1）（

0.05），肝癌临床分期Ⅱ-Ⅳ高于临床分期I（

0.05），肝癌G3-4分化高于G1-2分化（

0.05），复发患者高于未复发者（

0.05），预后不良者高于预后良好者（

0.05）；CDC25B高表达组患者的总生存率低于CDC25B低表达组（

0.05）。Hep3B和HepG2的细胞活力随着β-谷甾醇作用剂量增加、作用时间延长而降低，Hep3B（β-谷甾醇15 μmol/L）和HepG2（β-谷甾醇18 μmol/L）的相对克隆数目、S期细胞百分比均显著低于Control组（

0.05），而G0/G1期细胞百分比、细胞凋亡率均显著高于Control组（

0.05）。β-谷甾醇组移植瘤的体积、质量和Ki67相对表达水平均显著低于Control组（

0.05）。Hep3B和HepG2细胞中的CDC25B蛋白表达均随着β-谷甾醇浓度增加、作用时间延长而减低，Hep3B和HepG2细胞的β-谷甾醇+CDC25B组的细胞生长、相对克隆数目、S期细胞百分比均显著高于β-谷甾醇组（

0.05），而G0/G1期细胞百分比、细胞凋亡率均显著低于β-谷甾醇组（

0.05）。

结论

β-谷甾醇可促进肝癌细胞凋亡和抑制细胞增殖，其抑制细胞增殖可能与抑制CDC25B蛋白表达有关。

Abstract

Objective

To explore the effects and possible actions mechanisms of β-sitosterol on the proliferation of hepatocellular carcinoma （HCC） cells.

Methods

The target of β-sitosterol was predicted by SwissTarget and TargetNet data platforms. The up-regulated gene in GSE101728 HCC data set was analyzed by GEO2R， and the common gene between the target and the up-regulated gene was analyzed. According to the analysis of TCGA_LIHC data matrix， the relationship between cell division cyclin 25B （CDC25B） and clinical staging， prognosis of HCC was obtained. The activities， proliferation， cycles distribution and apoptosis of HCC cells （HepG2， Hep3B） treated with β-sitosterol were detected by CCK-8， colony-forming assay and flow cytometry. The models of nude mice with subcutaneous xenografted tumors in HepG2 were constructed and divided into control group and β-sitosterol group. The β-sitosterol group was intraperitoneally injected with β-sitosterol （50 mg/kg·d）. The volume and mass of tumors were measured. The expression level of Ki67 was detected by immunohistochemistry. The levels of CDC25B protein in HepG2 and Hep3B cell lines treated with different concentrations of β-sitosterol for different action time were detected by Western blot. HepG2 and Hep3B cell lines with stable overexpression of CDC25B were constructed， and then which were treated with β-sitosterol. The activities， proliferation， cycles distribution and apoptosis of HepG2 and Hep3B cell lines were detected by the above-mentioned methods.

Results

The expression level of CDC25B in HCC tissues was higher than that in para-carcinoma tissues （

0.05）. The expression level of CDC25B in patients with TNM staging at stage T2-4， clinical staging at stage Ⅱ-Ⅳ， G3-4 differentiation， recurrence and poor prognosis was higher than that with TNM staging at stage T1， clinical staging at stage I， G1-2 differentiation， non-recurrence and good prognosis， respectively （

0.05）. The overall survival rate in high-expression CDC25B group was lower than that in low-expression group （

0.05）. The activities of Hep3B and HepG2 cells were decreased with the increase of β-sitosterol dose and the prolongation of action time. The relative number of clone cells and the percentages of cells during S phase in Hep3B （15 μmol/L β-sitosterol） and HepG2 （18 μmol/L β-sitosterol） were significantly lower than those in control group （

0.05）， while percentage of cells during G0/G1 phase and apoptosis rate were significantly higher than those in control group （

0.05）. The volume and mass of xenografted tumors， and relative expression level of Ki67 in β-sitosterol group were significantly lower than those in the control group （

0.05）. The expression of CDC25B protein in Hep3B and HepG2 cells was decreased with the increase of β-sitosterol concentration and the prolongation of action time. The cells growth， relative number of clone cells， and percentages of cells during S phase in Hep3B and HepG2 cells were all significantly higher than those in β-sitosterol group （

0.05）， while percentage of cells during G0/G1 phase and apoptosis rate were significantly lower than those in β-sitosterol group （

0.05）.

Conclusion

The β-sitosterol can promote apoptosis of HCC cells and inhibited their proliferation. The inhibition of cells proliferation may be related to inhibition of CDC25B protein.

关键词

肝癌β-谷甾醇细胞分裂周期25B细胞增殖

Keywords

hepatocellular carcinomaβ-sitosterolcell division cyclin 25Bcell proliferation

references

Villanueva A. Hepatocellular carcinoma［J］. N Engl J Med， 2019， 380（15）：1450-1462.

Kulik L， El-Serag HB. Epidemiology and management of hepatocellular carcinoma［J］. Gastroenterology， 2019， 156（2）：477-491.

Dhanasekaran R， Nault JC， Roberts LR， et al. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy［J］. Gastroenterology， 2019， 156（2）：492-509.

Liu Y， Deng X， Wu D， et al. PKCδ promotes fertilization of mouse embryos in early development via the Cdc25B signaling pathway［J］. Exp Ther Med， 2019， 18（5）：3281-3290.

Cairns J， Ly RC， Niu N， et al. CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer ［J］. NAR Cancer， 2020， 2（4）：zcaa039-16.

Al-Matouq J， Holmes TR， Hansen LA. CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death ［J］. Mol Carcinog， 2019， 58（9）：1691-1700.

Vo TK， Ta QTH， Chu QT， et al. Anti-hepatocellular-cancer activity exerted by β-Sitosterol and β-Sitosterol-Glucoside from Indigofera zollingeriana Miq ［J］. Molecules， 2020， 25（13）：3021-2034.

牛丹丹，刘振，李方方. miR-146 a-5 p通过调控Notch2表达对心肌缺血再灌注模型大鼠心肌损伤的影响［J］.中国免疫学杂志，2020，（5）：530-537，554.

Niu DD， Liu Z， Li FF. Effects of miR-146a-5p on myocardial injury in rats induced by myocardial ischemia reperfusion by regulating expression of Notch2［J］. Chin J Immunol， 2020，（5）：530-537，554.

Varol Fİ. Pediatric hepatocellular carcinoma［J］. J Gastrointest Cancer， 2020， 51（4）：1169-1175.

Chang Y， Jeong SW， Young Jang J， et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma ［J］. Int J Mol Sci， 2020， 21（21）：8165-8185.

Zhou BX， Li J， Liang XL， et al. β-sitosterol ameliorates influenza A virus-induced proinflammatory response and acute lung injury in mice by disrupting the cross-talk between RIG-I and IFN/STAT signaling ［J］. Acta Pharmacol Sin， 2020， 41（9）：1178-1196.

Haiyuan YU， Shen X， Liu D， et al. The protective effects of β-sitosterol and vermicularin from Thamnolia vermicularis （Sw.） Ach. against skin aging in vitro［J］. An Acad Bras Cienc， 2019， 91（4）：e20181088-11.

Feng S， Dai Z， Liu AB， et al. Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet ［J］. Biochim Biophys Acta Mol Cell Biol Lipids， 2018， 1863（10）：1274-1284.

Soto-Rojas LO， Martínez-Dávila IA， Luna-Herrera C， et al. Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat ［J］. Acta Neuropathol Commun， 2020， 8（1）：56-81.

Shathviha PC， Ezhilarasan D， Rajeshkumar S， et al. β-sitosterol mediated silver nanoparticles induce cytotoxicity in human colon cancer HT-29 cells［J］. Avicenna J Med Biotechnol， 2021， 13（1）：42-46.

Hume S， Dianov GL， Ramadan K. A unified model for the G1/S cell cycle transition ［J］. Nucleic Acids Res， 2020， 48（22）：12483-12501.

李慧，汪根树，郑俊，等. Zwint高表达对肝癌细胞增殖和肝癌肝移植预后的影响［J］.器官移植，2018，9（2）：122-129.

Li H， Wang GS， Zheng J， et al. Effect of high expression of Zwint on the proliferation of hepatoma cells and the prognosis of liver transplantation for hepatocellular carcinoma［J］. Organ Transplant， 2018， 9（2）： 122-129.

牛义善，曾强.炎症生物标志物对肝癌肝移植预后的预测作用［J］.器官移植，2022，13（1）：49-54.

Niu YS， Zeng Q. Predictive effect of inflammatory biomarkers on prognosis of liver transplantation for hepatocellular carcinoma［J］. Organ Transplant， 2022， 13（1）： 49-54.

Rubin SM， Sage J， Skotheim JM. Integrating old and new paradigms of G1/S control ［J］. Mol Cell， 2020， 80（2）：183-192.

Zaiem F， Jerbi R， Albanyan O， et al. High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma［J］. Avicenna J Med， 2020， 10（4）：241-248.

Raj RK， D E， S R. β-Sitosterol-assisted silver nanoparticles activates Nrf2 and triggers mitochondrial apoptosis via oxidative stress in human hepatocellular cancer cell line［J］. J Biomed Mater Res A， 2020， 108（9）：1899-1908.

Aliotta F， Nasso R， Rullo R， et al. Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells［J］. J Enzyme Inhib Med Chem， 2020， 35（1）：1866-1878.

Jia J， Li H， Chu J， et al. LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis ［J］. J Cancer， 2021， J12 （4）：1200-1211.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

长链非编码RNA GAPLINC对类风湿关节炎成纤维样滑膜细胞增殖表型的影响

乳酸脱氢酶A在肾细胞癌中的表达及意义

¹³¹I标记的肝癌核酸纳米火车的制备及生物分布研究

DNA损伤修复基因FANCI与肝癌预后和免疫浸润相关性

肝脏分隔及门静脉右支结扎术后肝内门静脉侧支血管开放与肝组织增生关联分析